Skip Ribbon Commands
Skip to main content
Sign In
Navigate Up

25597 Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum

Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
Test Code: NMOFSSO
Synonyms/Keywords
NMO/AQP4 FACS Assay with reflex to Titer
Test Components
When the results of this assay require further evaluation, NMOTS/Neuromyelitis Optica (NMO)/Auaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Titer Assay, Serum will be performed at an additional charge.
Useful For

Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)

Diagnosis of autoimmune AQP4 channel therapy

Diagnosis of neuromyelitis optica (NMO)

Distinguishing NMOSD from multiple sclerosis early in the course of disease

Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
​No ​Serum ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​3.0 mL ​2.0 mL ​
Collection Processing Instructions
Submit a serum sample from a red top or serum gel tube. Include relevant clinical information.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Refrigerated (preferred) ​28 days
​Ambient ​72 hours
​Frozen ​28 days
Interference
​AQP4-IgG antibodies may drop below detectable levels in setting of therapies for acute attack (IV methylprednisolone or plasmapheresis) or attack prevention (immunosuppressants).
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday, Tuesday, Thursday at 6pm ​5 days Flow Cytometry
Reference Lab
Mayo Clinic Laboratories
Reference Range Information
Negative
Interpretation
​A positive value is consistent with a neuromyelitis optica spectrum disorder (NMOSD) and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 3 to 6 months if NMOSD is suspected.
 
This autoantibody is not found in healthy subjects.
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​86255 ​ ​1 ​Fluorescent noninfectious agent antibody; screen each, antibody ​
​86256 ​ ​1 ​Fluorescent noninfectious agent antibody; titer, each antibody ​If needed
Synonyms/Keywords
NMO/AQP4 FACS Assay with reflex to Titer
Test Components
When the results of this assay require further evaluation, NMOTS/Neuromyelitis Optica (NMO)/Auaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Titer Assay, Serum will be performed at an additional charge.
Ordering Applications
Ordering Application Description
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)		 Pediatric Minimum Volume
(no repeat)
​No ​Serum ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​3.0 mL ​2.0 mL ​
Collection Processing
Submit a serum sample from a red top or serum gel tube. Include relevant clinical information.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Refrigerated (preferred) ​28 days
​Ambient ​72 hours
​Frozen ​28 days
Interference
​AQP4-IgG antibodies may drop below detectable levels in setting of therapies for acute attack (IV methylprednisolone or plasmapheresis) or attack prevention (immunosuppressants).
Useful For

Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)

Diagnosis of autoimmune AQP4 channel therapy

Diagnosis of neuromyelitis optica (NMO)

Distinguishing NMOSD from multiple sclerosis early in the course of disease

Test Components
When the results of this assay require further evaluation, NMOTS/Neuromyelitis Optica (NMO)/Auaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Titer Assay, Serum will be performed at an additional charge.
Reference Range Information
Negative
Interpretation
​A positive value is consistent with a neuromyelitis optica spectrum disorder (NMOSD) and justifies initiation of appropriate immunosuppressive therapy at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 3 to 6 months if NMOSD is suspected.
 
This autoantibody is not found in healthy subjects.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday, Tuesday, Thursday at 6pm ​5 days Flow Cytometry
Reference Lab
Mayo Clinic Laboratories
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)		 Quantity Description Comments
​86255 ​ ​1 ​Fluorescent noninfectious agent antibody; screen each, antibody ​
​86256 ​ ​1 ​Fluorescent noninfectious agent antibody; titer, each antibody ​If needed
For most current information refer to the Marshfield Laboratory online reference manual.